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Purpose:  Bacteremia is a major infectious complication 
associated with mortality in liver transplant recipients. The 
causative organisms and clinical courses differ between medical 
centers due to variations in regional bacterial epidemiology 
and posttransplant care. Further, living donors in Korea con-
tribute to 83% of liver transplants, and individualized data are 
required to improve survival rates. Patients and Methods: We 
retrospectively analyzed 104 subjects who had undergone 
living-donor liver transplant from 2005 to 2007. Results: Among 
the 144 consecutive living-donor liver transplant recipients, 
24% (34/144) developed bacteremia, 32% (46/144) developed 
non-bacteremic infections, and 44% (64/144) did not develop 
any infectious complications. Forty episodes of bacteremia 
occurred in 34 recipients. The major sources of bacteremia 
were intravascular catheter (30%; 12/40), biliary tract (30%; 
12/40), and abdomen (22.5%; 9/40). Gram-positive cocci were 
more common (57.5%; 23/40) than Gram-negative rods (32.5 
%; 13/40) and fungi (10%; 4/40). The data revealed that the 
following factors were significantly different between the 
bacteremia, non-bacteremic infection, and no infection groups: 
age (p = 0.024), posttransplant hemodialysis (p = 0.002), ICU 
stay (p = 0.012), posttransplant hospitalization (p < 0.0001), 
and duration of catheterization (p < 0.0001). The risk factors 
for bacteremia were older than 55 years (odds ratio, 6.1; p = 
0.003), catheterization for more than 22 days (odds ratio, 4.0; 
p = 0.009), UNOS class IIA (odds ratio, 6.6; p = 0.039), and 
posttransplant hemodialysis (odds ratio, 23.1; p = 0.001). One- 
year survival rates in the bacteremic, non-bacteremic infection, 
and no infection groups were 73.2%, 91.3%, and 93.5%, 
respectively. Conclusion: Early catheter removal and preserva-
tion of renal function should focus for improving survival after 
transplant.
Key Words: Living-donor liver transplant, bacteremia, risk 
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INTRODUCTION 
Bacteremia has been reported to be the main 
cause of mortality in liver transplant recipients.
1-3 
The mortality in bacteremic liver transplant reci-
pients has been found to range between 24% and 
36%.
4,5 In a previous study, it was found that the 
proportion of all infections due to bacteremias 
increased significantly over time. Furthermore, of 
other major infections, a trend of fungal infection 
and cytomegalovirus infection to decrease was 
noted.
6 Most bacterial infections in liver transplant 
recipients occur within the first month after trans-
plantation, with the incidence of bacteremia 
ranging between 21% and 33%.
7,8
The proportions of types bacterial infections 
have changed since the early 1990s, and differ-
ences have also been noted in the proportions 
among hospitals. Several centers have reported 
that the infections due to Gram-negative bacteria 
constitute 65% of all types of bacterial infections, 
resulting from intra-abdominal or biliary sources.
7-9 
In contrast, some centers have reported that 
infections due to Gram-positive bacteria, such as 
staphylococci and enterococci, outnumber those 
due to Gram-negative bacteria.
10,11 Diabetes and 
serum albumin levels are significant clinical pre-
dictors for bacteremia in liver transplant recipients.
12 
However, characteristics of donors, hospital envir-Bacteremia after Living-Donor Liver Transplantation 113
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onment, antibacterial prophylaxis, regional bacte-
rial epidemiology, and posttransplant managements 
differ among centers. Further, living donors in 
Korea contribute to more than 80% of liver trans-
plants.
13-15 Therefore, clinical predictors need to be 
reassessed to improve the survival. 
PATIENTS AND METHODS 
Patients 
We analyzed 144 patients who had undergone 
living-donor liver transplant from January 2005 to 
September 2007 at Kangnam St. Mary's hospital, 
Seoul, Korea-a 1,000-bed tertiary-care university 
hospital. 
Antimicrobial prophylaxis 
The perioperative prophylaxis consisted of cefo-
perazone/sulbactam (2 g/day, IV) and ampicillin 
(8g/day, IV) for 5 days. Nystatin (800,000 units/ 
day, oral) was administered for 1 month for fungal 
prophylaxis. Pneumocystis pneumonia prophylaxis 
consisted of trimethoprim/sulfamethoxazole (80 
mg/400 mg/day, oral). Routine antiviral prophyl-
axis was not administered.
Immunosuppression 
All patients received tacrolimus or cyclosporine, 
mycophenolate mofetil, and low-dose prednisone 
as routine immunosuppressive agents. Rejections 
were treated with a high-dose steroid along with 
or without change in the immunosuppressive 
agents to tacrolimus or OKT3. 
Definition of bacteremia and infection 
We used a previously reported diagnostic de-
finition of infection in transplant recipients.
16 
Bacteremia was considered to be present when 
Staphylococcus aureus,  Candida species, or Gram- 
negative rods were isolated from at least 1 blood 
culture. The other pathogens were considered 
positive when they were isolated from 2 blood 
cultures from the site considered as the infection 
site. Primary bacteremia was defined as bacteremia 
with no physical, radiological, or pathological 
evidence of a definite infection source. Catheter- 
related bacteremia was defined when more than 
15 colony-forming units of bacteria were cultured 
from the catheter tip, irrespective of whether the 
same organism was isolated from the blood 
culture. Intra-abdominal infection was defined as 
presence of fever, abdominal pain, tenderness, or 
elevation of liver function indices with evidence 
of cholangitis, liver abscess, or infected biloma 
through radiological examination. These definitions 
were also stated in the Center for Disease Control 
criteria.
17
Statistical analysis 
Student's t-test was used to analyze the continu-
ous variables, and chi-square test was used to 
analyze the categorical variables. We analyzed the 
risk factors associated with bacteremia by univari-
ate and multivariate logistic regression analyses. 
Statistical analysis was performed using SPSS for 
Windows, version 12.0 software package (SPSS 
Inc, Chicago, IL, USA) and p values less than 0.05 
was considered to be statistically significant. 
RESULTS
Among the 144 consecutive patients who had 
undergone living-donor liver transplant from 
January 2005 to September 2007, bacteremia de-
veloped in 23.6% (34/144) of the patients, whereas 
31.9% (46/144) of the patients developed non- 
bacteremic infections. These patients developed 
infectious complications after the transplant, how-
ever, no pathogenic microorganisms were detected 
from the blood. Infectious complications did not 
occur in 44% (64/144) of the patients. The number 
of follow-up days was 525 ± 319 days (mean ± SD). 
Viral hepatitis with the hepatitis B virus was the 
predominant underlying liver disease. The mean 
age of patients with bacteremia was 52.5 years, 
with non-bacteremic infection was 47.4 years, and 
without infection was 47.9 years, with a significant 
difference between the 3 groups (p = 0.024) and 
also between the bacteremia and non-bacteremic 
infection groups (p = 0.039). Combined diseases such 
as diabetes, tumors, and renal dysfunction did not Sang Il Kim, et al. 114
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Table 1. Demographic and Clinical Characteristics of Living-Donor Liver Transplant Recipients*
  Bacteremia
(n = 34)
Non-bacteremic infection
(n = 46)
No-infection
(n = 64) p value
† p value
‡
Sex, % of male 76.5% (26/34)  73.9% (34/46) 82.8% (53/64) 0.507  
Age (yrs) 52.5 ± 6.4 47.4 ± 10.1 47.9 ± 9.0 0.024 0.039
Underlying liver disease     0.399  
Alcoholic 8.8% (3/34) 13.0% (6/46) 6.3% (4/64)   
Viral hepatitis        
Hepatitis B 85.3% (29/34) 65.2% (30/46) 76.6% (49/64)   
Hepatitis C 0  2.2% (1/46) 4.7% (3/64)   
NBNC 0 8.7% (4/46) 6.3% (4/64)   
Autoimmune  2.9% (1/34) 2.2% (1/46) 0    
Drug related  2.9% (1/34) 2.2% (1/46) 0   
Unknown 0 6.5% (3/46) 6.3% (4/64)   
Combined disease        
Tumor 55.9% (19/34) 39.1% (18/46) 46.9% (30/64) 0.331  
Diabetes mellitus 29.4% (10/34) 30.4% (14/46) 29.7% (19/64) 0.766  
Renal dysfunction 11.8% (4/34) 6.5% (3/46) 4.7% (3/64) 0.419  
Pre-transplant condition        
MELD score  17.0 ± 9.5 18.3 ± 8.7 15.1 ± 8.2 0.161  
Child-pugh score  9.2 ± 2.6  9.5 ± 2.4  8.9 ± 2.7 0.509  
UNOS class IIA 20.6% (7/34)   10.9% (5/46) 6.3% (4/64)  0.134  
NBNC, non-B non-C; MELD, model for end-stage liver disease; UNOS, united network of organ sharing.
*Data are presented as percent (no.) or mean ± SD.
†Chi-square test was used to analyze categorical variables between three groups and ANOVA for continuous variables.
‡Student's t-test was used between bacteremia group and non-bacteremic infection group.
differ between the 3 groups. Pre-transplant para-
meters such as the Model for End-Stage Liver 
Disease (MELD) scores, Child-Pugh scores, and 
United Network of Organ Sharing (UNOS) classes 
did not significantly differ between the 3 groups 
(Table 1). 
Sources and causes of bacteremia
Of the 144 patients, 34 had 40 episodes of bacte-
remia, and 17% (6/34) of these patients experienced 
an additional bacteremia episode during the study 
period. None of these patients showed relapse or 
recurrence of bacteremia, and each episode was 
considered a different case. Among 40 episodes of 
bacteremia, 22.5% (9/40) occurred within 14 days 
of operation and 77.5% (31/40) occurred later than 
14 days after transplantation.
The 3 most common sources of bacteremia were 
intravascular catheter (30%; 12 of 40 episodes), 
biliary tract (30%; 12 of 40 episodes), and abdomen 
(22.5%; 9 of 40 episodes). The sources and patho-
gens in bacteremic patients are listed in Table 2. 
Catheter-related bacteremia in the majority of the 
cases was caused by staphylococci (75.0%; 9 of 12 
episodes). Of them, 88.9% (8 of 9 organisms) were 
methicillin-resistant. Two patients died due to 
catheter-related bacteremia caused by Candida 
albicans and Acinetobacter lwoffii.
The data revealed that Gram-positive cocci (57.5 
%; 23 of 40 episodes) were more common than 
Gram-negative rods (32.5%; 13 of 40 episodes).Bacteremia after Living-Donor Liver Transplantation 115
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Table 2. Sources and Pathogens Associated with Bacteremia in Study Patients
Source
(No. of episodes)
Pathogen No. of episodes
Sensitivity to major antibiotics 
(No. of episodes) 
Catheter related (n = 12) Coagulase-negative Staphylococci 7  
  Staphylococcus  epidermidis 4 MR  (4)
  Staphylococcus  hominis 2 MR (1), MS (1)
  Staphylococcus  haemolyticus 1M R  ( 1 )
Staphylococcus aureus  2M R  ( 2 )
Acinetobacter lwoffii 1C S  ( 1 )
Candida albicans 1F S  ( 1 )
Candida parapsilosis 1F R  ( 1 )
Biliary (n = 12) Enterococcus faecium 3 VR (2), VS (1)
Enterococcus casseliflavus 1V R  ( 1 )
Klebsiella pneumoniae 3 ESBL (1), non-ESBL (2)
Escherichia coli 2n o n - E S B L  ( 2 )
Pseudomonas aeruginosa 1n o n - E S B L  ( 1 )
Enterobacter cloacae 1E S B L  ( 1 )
Candida species* 1  
Abdomen (n = 9) Enterococcus faecium 5 VR (3), VS (2)
Escherichia coli 2n o n - E S B L  ( 2 )
Acinetobacter baumannii 1C S  ( 1 )
Candida glabrata 1F R  ( 1 )
Pneumonia (n = 2) Streptococcus pneumoniae 1C S  ( 1 )
Chryseobacterium meningosepticum 1C R  ( 1 )
Wound (n = 1) Staphylococcus aureus 1M R  ( 1 )
Urinary tract (n = 1) Enterococcus faecium 1V S  ( 1 )
Unknown (n = 3) Staphylococcus epidermidis
† 2 MR (1), MS (1)
Empedobacter brevis 1C R  ( 1 )
MR, methicillin resistant; MS, methicillin sensitive; CS, cephalosporin sensitive; CR, cephalosporin resistant; FS, fluconazole sensitive; 
FR, fluconazole resistant; VR, vancomycin resistant; VS, vancomycin sensitive; ESBL, extended-spectrum beta lactamase positive; 
non-ESBL, extended-spectrum beta lactamase negative.
*Species were not demonstrated at the point of detected.
† Both 2 episodes fulfilled the definition for primary bacteremia.
Among the Gram-positive cocci, methicillin-resis-
tant coagulase-negative staphylococci (30.4%; 7/23) 
were the most common, followed by vancomycin- 
resistant enterococci (26.1%; 6/23), vancomycin- 
sensitive enterococci (17.4%; 4/23), methicillin- 
resistant S. aureus (13%; 3/23), methicillin-sensitive 
coagulase-negative staphylococci (8.7%; 2/23), and 
penicillin-resistant pneumococci (4.3%; 1/23). Over-
all, 26.1% (6 of 23 Gram-positives) of the Gram- 
positive cocci were resistant to vancomycin. None 
of the enterococci were resistant to linezolid.
The most common Gram-negative rod was 
Escherichia coli (30.8%; 4/13), followed by Klebsiella 
pneumoniae (23.1%; 3/13) and Acinetobacter baumannii Sang Il Kim, et al. 116
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Table 3. Pre-operative Variables with Bacteremia Compared t o  N o n - B a c t e r e m i c  I n f e ctions and No-Infection*
 
Bacteremia
(n = 34)
Non-bacteremic infection
(n = 46)
No-infection
(n = 64)
p value
†
Donor relationship     0.912
Offspring  47.1% (16/34)  43.5% (20/46) 43.8% (28/64)  
Sibling 20.6% (7/34) 21.7% (10/46) 15.6% (10/64)  
Parent 0 2.2%  (1/46) 1.6%  (1/64)  
Distant family 0 4.3% (2/46) 6.3% (4/64)  
Conjugal 11.8% (4/34) 8.7% (4/46) 15.6% (10/64)  
Unrelated 20.6% (7/34) 19.6% (9/46) 17.2% (11/64)  
Positive lymphocyte crossmatch 6.9% (2/34) 11.8% (4/46) 3.4% (2/64) 0.300
History of Previous operation 11.8% (4/34) 13.0% (6/46) 9.4% (6/64) 0.825
Pre-operational infectious disease      
Fever of unproven source 11.8% (4/34) 17.4% (8/46) 7.8% (5/64) 0.307
Infectious disease     0.309
SBP 17.6% (6/34) 15.2% (7/46) 4.7% (3/64)  
Pneumonia 0 0 3.1% (2/64)  
Sinusitis 5.9% (2/34) 4.3% (2/46) 7.8% (5/64)  
Cholecystitis 2.9% (1/34) 0 0  
Tuberculosis 0 2.2% (1/46) 1.6% (1/64)  
Others 5.9% (2/34) 6.5% (3/46) 1.6% (1/64)  
None 67.6% (23/34) 71.7% (33/46) 81.3% (52/64)  
Pre-operational non-infectious variables      
    Acute hepatic failure 23.5% (8/34) 26.1% (12/46) 18.8% (12/64) 0.645
   Portal vein thrombosis 14.7% (5/34) 8.7% (4/46) 20.3% (13/64) 0.246
   Small graft size 0 6.5% (3/46) 7.8% (5/64) 0.259
Laboratory findings       
White blood cell count (/mm
3) 4,264 ± 3,181 4,089 ± 2,894 3,649 ± 2,498 0.529
Creatinine (mg/dL) 0.96 ± 0.74 0.81 ± 0.38 1.03 ± 1.32 0.502
Total bilirubin (mg/dL) 11.6 ± 13.4 10.9 ± 11.9 7.2 ± 10.3 0.116
Albumin (mg/dL) 3.2 ± 0.5 3.1 ± 0.5 3.2 ± 0.5 0.987
SGPT (IU/L) 50 ± 41 57 ± 77 48 ± 51 0.709
INR  1.6 ± 0.4 1.9 ± 1.0 1.6 ± 0.5 0.067
SBP, spontaneous bacterial peritonitis; SGPT, serum glutamate pyruvate transaminase; INR, international normalized ratio.
*Data are presented as percent(no.) or mean ± SD.
† Chi-square test was used to analyze categorical variables between three groups and ANOVA for continuous variables.
(15.4%; 2/13). Among the Gram-negatives, 46.2% 
(6/13) demonstrated resistance to third-generation 
cephalosporins such as ceftazidime, ceftriaxone, 
and cefoperazone. Furthermore, most of the organ-
isms that were resistant to third-generation ceph-
alosporins also showed resistance to piperacillin- Bacteremia after Living-Donor Liver Transplantation 117
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Table 4. Intra-Operative and Post-Operative Variables of Bacteremic Group Compared to Non-Bacteremic Infection 
and No Infection*
 
Bacteremia
(n = 34)
Non-bacteremic infection
(n = 46)
No-infection
(n = 64)
p value
† p value
‡
Intraoperative variables
Operative duration 
(min, min ± SD)
640 ± 94  645 ± 103 613 ± 72 0.150
RBC transfusion 
(packs, min ± SD)
15.3 ± 8.4  15.2 ± 10.4 12.4 ± 6.7 0.143
Post-operative variables
Re-operation  8.8% (3/34) 15.2% (7/46) 6.3% (4/64) 0.288
Hemodyalisys 26.5% (9/34) 10.9% (5/46) 3.1% (2/64) 0.002
ICU stay (days)  15.6 ± 23.6 10.0 ± 7.1  7.6 ± 2.0 0.012 0.009
Catheter days (days)  29.6 ± 22.6 17.5 ± 6.2 16.6 ± 6.4 < 0.0001 < 0.0001
Biliary complication 26.5% (9/34) 37.0% (17/46) 18.8% (12/64) 0.102
Duration of hospitalization
Post-operation  38.9 ± 22.1  35.7 ± 21.4 25.3 ± 6.6 < 0.0001 < 0.005
ICU, intensive care unit.
*Data are presented as percent (no.) or mean ± SD.
† Chi-square test was used to analyze categorical variables between three groups and ANOVA for continuous variables.
‡ Student's t-test was used between bacteremia group and non-bacteremic infection group.
tazobactam (data not shown). Fungi caused 10% 
(4 of 40 episodes) of the episodes, and 50% of these 
fungi were resistant to fluconazole.
Predictors of bacteremia 
The perioperative clinical and laboratory vari-
ables predictive of post-transplant bacteremia 
were compared between bacteremia, non-bactere-
mic infection, and no infection groups (Table 3). 
No difference was noted between the groups with 
regard to preoperative variables such as donor 
relationship, positive lymphocyte cross-match, 
history of previous surgery, presence of preope-
rative infectious disease, and laboratory findings. 
The intraoperative and postoperative variables of 
the recipients are listed in Table 4. Surgery dura-
tion and the amount of transfusion did not differ 
between groups. However, bacteremic patients 
were significantly more likely to have undergone 
posttransplant hemodialysis (p = 0.002), and to have 
longer duration of ICU stay (p = 0.012) and longer 
period of intravascular catheterization (p < 0.0001). 
Postoperative hospitalization period was longer in 
bacteremic patients than in patients with non- 
bacteremic infection (p = 0.005). 
Risk factors for bacteremia and mortality 
Univariate analysis revealed that age above 55 
years (p = 0.014), intravascular catheterization for 
more than 8 days (p = 0.003), UNOS class IIA (p = 
0.044), and hemodialysis (p = 0.001) were significant 
risk factors for bacteremia (Table 5). Multivariate 
analysis revealed an association between bacteremia 
and age (odds ratio, 6.05; 95% confidence interval, 
1.86 to 19.66; p = 0.003), catheterization for more 
than 22 days (odds ratio, 3.97; 95% confidence 
interval, 1.4 to 11.22; p = 0.009), UNOS class IIA 
(odds ratio, 6.59; 95% confidence interval, 1.1 to 
39.37; p = 0.039), and posttransplant hemodialysis 
(odds ratio, 23.12; 95% confidence interval, 3.78 to 
141.55;  p = 0.001).
Of the 144 patients, 11.8% (17/144) died. Of 
these, 52.9% (9/17) had episodes of bacteremia, 
23.5% (4/17) had episodes of non-bacteremic infec-Sang Il Kim, et al. 118
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Table 5. Logistic Regression Analysis of Risk Factors for Bacteremia after Living-Donor Liver Transplant
Risk factors
Percentage of bacteremia 
with risk factor (No.*)
p  value
(univariate)
p value
(multivariate)
OR (95% CI)
Preoperational variables
 Age  (yrs)  ≥ 55
        <5 5  
36.2% (17/47) 
17.5% (17/97)
0.014 0.003
 6.05 
(1.86-19.66)
 Diabetes    Yes
            No
21.9% (7/32)
24.1% (27/112)
0.793   
 UNOS  class  IIA 
IIB or III
43.8% (7/16)
21.1% (27/128)
0.044 0.039
   6.59  
(1.10-39.37) 
 Child  class  C 
    A or B
22.1% (17/77)
25.4% (17/67)
0.642   
 MELD  score  ≥ 25
             <2 5
29.0% (9/31)
22.1% (25/113)
0.422   
 Tumor     Yes
            No 
28.4% (19/67)
19.5% (15/77)
0.211   
  History of previous surgery   Yes
            No
25.0% (4/16) 
23.4% (30/128)
0.890 
 
  
 Renal  dysfunction  Yes
                  No
40.0% (4/10)
22.4% (30/134)
0.206   
  Portal vein thrombosis  Yes
                  No
22.7% (5/22) 
23.8% (29/122) 
0.916 
 
  
Intra- and post-operational variables 
  Duration of operation (h)  ≥ 10
<1 0
22.4% (19/85)
25.4% (15/59)
0.670   
 Re-operation  Yes
              No
21.4% (3/14)
23.8% (31/130)
0.840   
 Posttransplant  hemodialysis Yes
            No
56.3% (9/16)
19.5% (25/128)
0.001 0.001
23.12
(3.78 - 141.55)
 Bilary  complication  Yes
            No
23.7% (9/38) 
23.6% (25/106) 
0.990   
 ICU  stay(d)  ≥ 8 
            <8   
22.6% (14/62)
24.4% (20/82)
0.800   
 Catheter  days  ≥ 22
             <2 2   
39.1% (18/46)
16.3% (16/98)
0.003 0.009
 3.97 
(1.40 - 11.22)
OR, odd ratio; CI, confidence interval; UNOS, united network of organ sharing; MELD, model for end-stage liver disease; ICU, 
intensive care unit.
*No. of bacteremia/No. of patients with risk factors.
tions, and 23.5% (4/17) did not have any infec-
tious complication. The mortality rates were 26.5% 
(9/34) in bacteremia group, 8.7% (4/46) in non- 
bacteremic infection group, and 6.3% (4/64) in no 
infection group, respectively. The causative orga-
nisms related to death in bacteremia group were 
4 enterococci including 2 vancomycin-resistant 
strains, 2 Acinetobacter species, 1 E. coli, and 3  Bacteremia after Living-Donor Liver Transplantation 119
Yonsei Med J Vol. 50, No. 1, 2009
Fig. 1. Survival curves of study groups; the survival rate 
at 1 month: bacteremia group, 94.1%; non-bacteremic 
infection group, 95.7%; and no infection group, 95.3%, the
survival rate at 12 months: bacteremia group, 73.2%; non-
bacteremic infection group, 91.3%; and no infection group,
93.5%. It was statistically different between the groups as 
follows: bacteremia vs. no infection, p = 0.006; bacteremia
vs. non-bacteremic infection, p = 0.044. No difference was 
noted between the no infection and non-bacteremic 
infection groups (p =0 . 6 5 ) .  
candidemias. One patient developed Candida and 
enterococci bacteremia simultaneously. Of the 46 
patients in the non-bacteremic infection group, 4 
died: 1 due to multi-drug resistant Acinetobacter 
pneumonia, 1 due to Aspergillus pneumonia, 1 due 
to refractory shock with pneumonia and infected 
hematoma, and 1 due to pneumonia with ischemic 
heart disease. Of 64 patients in the no infection 
group, 4 died: 1 due to primary graft failure, 2 due 
to varix bleeding, and 1 due to cardiac ischemia.
The survival rate at 1 month was as follows: 
bacteremia group, 94.1%; non-bacteremic infection 
group, 95.7%; and no infection group, 95.3% (Fig. 
1). However, the survival rate at 12 months was 
as follows: bacteremia group, 73.2%; non-bactere-
mic infection group, 91.3%; and no infection group, 
93.5%. It was statistically different between the 
groups as follows: bacteremia vs. no infection, p = 
0.006; bacteremia vs. non-bacteremic infection, p = 
0.044. No difference was noted between the no infec-
tion and non-bacteremic infection groups (p = 0.65).
DISCUSSION 
In this study, patients who developed bacteremia 
after liver transplantation had a decreased 1-year 
survival rate compared to patients who developed 
non-bacteremic infection (p = 0.044) or who did not 
develop any infectious complications (p =0 . 0 0 6 ) .  N o  
difference was noted in the survival rate between 
the patients who developed non-bacteremic infec-
tion and those who did not develop any infection 
(p = 0.650). Even though all the cases of mortality 
did not occur because of bacteremia, major causes 
of death were infectious complications with bac-
teremia rather than rejection, surgical complica-
tions, and non-bacteremic infections. Despite im-
provements in surgical technique, prolonged graft 
function, and progress in therapeutic options, the 
rate of major infectious complications remains 
high.
2 Technical complexity due to the high rate 
of bile leakage has been the main factor respon-
sible for infectious complications.
18 Our data 
revealed that the biliary tract was one of the most 
common sources of bacteremia (Table 2). In the 
present study, biliary complications were not sig-
nificantly different between the groups, however, 
reduction of biliary complications is thought to be 
important in reducing bacteremia, especially in 
living-donor liver transplantation, because biliary 
trees are one of the most common entries of 
bacteria and surgical technique is complex.
Liver transplant recipients are generally immu-
nocompromised.
1 Furthermore, the pretransplant 
conditions between patients are considerably vari-
able, and therefore, can be minimally controlled. 
Except for age, the uncontrollable pretransplant 
variables such as underlying liver disease, donor 
relationship, lymphocyte mismatch, and history of 
surgery did not differ between the groups. More-
over, pretransplant conditions such as laboratory 
findings and presence of infectious and non-infec-
tious diseases, including portal vein thrombosis, 
did not differ between the groups. These results 
indicated that posttransplant managements, short 
duration of ICU stay, early catheter removal, and 
short duration of hospital stay are important factors 
in reducing the rate of bacteremia. However, these 
results differ from those of a previous study in 
which diabetes, pretransplant renal dysfunction, 
and hypoalbuminemia were found to be indepen-
dently significant predictors of bacteremia in liver 
transplant recipients.
12 An improvement in the 
general care or change in the posttransplant care Sang Il Kim, et al. 120
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could have led to these differences. 
In our study, patients who developed bacteremia 
had undergone posttransplant hemodialysis more 
frequently than other patients and had longer 
duration of ICU stay and longer period of intra-
vascular catheterization. These results are not very 
different from those observed in a larger study.
9,12 
The independent risk factors for bacteremia were 
age above 55 years, catheterization for more than 
22 days, UNOS class IIA, and posttransplant 
hemodialysis. However, in a previous study, only 
diabetes mellitus and serum albumin level were 
found to be the risk factors for bacteremia.
12 This 
indicates that our medical center performs cathe-
terization for a longer period and needs to improve 
posttransplant care. In a previous study, age above 
65 years, donor age above 50 years, male gender 
recipient, re-transplant, and pretransplant MELD 
score greater than 25 were associated with poor 
patient and graft survival.
19 Furthermore, a high 
MELD score was found to be indicative of poor 
outcome and showed maximal impact during the 
first year posttransplant. Our data also revealed 
that bacteremic patients tended to have a higher 
MELD score than other patients, nevertheless it 
was not a significant risk factor. Therefore, we 
analyzed 4 variables of the MELD score separately 
to determine which factors were directly related 
to bacteremia. In the above mentioned study,
19 
recipients above the age of 65 years showed signi-
ficantly lower survival rates, whereas age above 
55 years was found to be a significant risk factor 
for bacteremia in our study. However, old age is 
a well-known risk factor for bacteremia even in 
non-transplant patients.
20 Combined tumor, largely 
hepatoma, was more common in bacteremic 
patients than in other patients, however, was not 
significant.
Catheter-related infection was the main cause of 
bacteremia; this has also been reported in a 
previous study.
12 However, the common etiologic 
organisms such as methicillin-resistant S. aureus 
and coagulase-negative staphylococci differ between 
centers.
12,21,22 At our center, coagulase-negative 
staphylococci were found to be more common 
than  S. aureus. Clinically, it is of importance to 
note that 88% of the staphylococci were methi-
cillin-resistant. Therefore, it can be suggested that, 
whenever a patient develops fever, glycopeptide 
should be added empirically during the pending 
blood culture in addition to removing the catheter. 
Furthermore, 26.1% of the Gram-positive cocci 
were vancomycin-resistant enterococci, therefore, 
linezolid can be considered when a patient is 
febrile 48 to 72 hours after glycopeptide admini-
stration even when no growth is detected in the 
blood culture.
One-year survival rate showed a significant 
difference between the 3 groups, whereas 1-month 
survival rate did not differ between the 3 groups: 
bacteremia group 94.1%; non-bacteremic infection 
group, 95.7%; and no infection group, 95.3% (Fig. 
1). Majority of the deaths occurred between 1 and 
6 months. Posttransplant infection within 1 month 
occurs primarily due to surgical and technical 
complexity, wound infection, urinary tract infec-
tion, catheter-related infection, and pneumonia.
1,2 
Our data revealed that a large percentage of events 
related to bacteremia occurred within 1 month, 
although death occurred between 1 and 6 months 
after transplant. Furthermore, long hospital stay 
along with hemodialysis or catheterization could 
be another factors responsible for bacteremia that 
contribute to the decreased survival rate in liver 
transplant recipients.
23 The limitations of our data 
are that, since this is a retrospective analysis, we 
could not identify the precise operational break-
age during the transplant that could have an effect 
on the posttransplant clinical course and also 
could not evaluate biliary variation in donors, 
which could be an important factor. A large 
prospective study in the future can provide more 
informative data.
In conclusion, posttransplant bacteremia de-
creases the 1-year survival rate in liver transplant 
recipients. To reduce the occurrence of bacteremia, 
recipients with older than 55 years of age and 
UNOS class IIA need to be carefully monitored for 
bacteremia, and antibacterial agents should be 
changed or added for resistant organisms based 
on the epidemiologic data. Early catheter removal 
and preservation of renal function could improve 
posttransplant survival. 
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